http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박중원 ( Joong Won Park ) 대한소화기학회 2005 대한소화기학회지 Vol.45 No.4
Hepatocellular carcinoma (HCC) is a highly malignant, generally fatal neoplasm arising from hepatocytes. HCC accounts for over 80% of all primary liver cancers which ranks fourth among the organ-specific causes of cancer-related deaths worldwide. HCC is p
만성 B형 간염환자에서 재조합형 알파 인터페론 저용량 단기 치료법의 효과
박중원(Joong won Park),유병철(Byung Chul Yoo),박실무(Sil Moo Park) 대한소화기학회 1995 대한소화기학회지 Vol.27 No.1
N/A Background/Aims: We planed the study to cvaluate the effect of low dose, short term therapy of recombinant alpha-interferon(IFN) in patients with chronic hepatitis B. Methods: Seventy two patients treated with IFN and 32 controls were included in the study. All l04 patients had serum HBsAg, HBeAg and biopsy proven chronic hepatitis B. The treated group received alpha IFN 2a 300 million units daily for four weeks, total 8400 million units. Effects of therapy on aminotransferase activities and HBsAg, HBeAg, anti-Hbe status in serum was monitored. The criterion of complete response was loss of serum HBeAg and normalization of serum aspartate aminotransferase(AST)/alanin aminotransferase(ALT), that of partial response was loss of serum HBeAg or normalization of serum AST/ALT within 8 weeks after IFN trial. The mean follow-up period was 20.6 months(treated group)and 45.8 months(control). Results: The complete responders were 18 patients(25%), the partial responders 24 patients(33.3%) and the non- responders 30 patients(41.7/o). The only difference between tbe responders and the non-responders in clincal features was AST activity. Loss of serum HBeAg within 8 weeks after IFN trial occurred in 23(3l.9%) patients and 13(l8.1%) patients had anti-Hbe seroconversion within 3 months after IFN trial. Eleven patients(l5.3%) of complete responders had normal AST/ALT for mean J9.2 months. Two of Eleven percents patients had scrum anti-HBs. Within mean 20.6 month follow-up period, 34(47.2%) patients had serum anti-Hbe and l9(26.4%) patients had that for more than 12 months. Thirty four of 72(47.2%) patients receiving interferon responded by anti-Hbe seroconversion within mean 20.6 months, compared to 13 of 32(40%) controls within 45.8 months(p<0.01). Conclusions: These findings indicate that a short course(4 weeks) of low dose recombinant alpha-interferon can induce an anti-Hbe seroconversion and an improvement of serum aminotransferase activities for significant duration in approximately one-fourth or fifth of treated patients with chronic hepatitis B and that low dose, short term recombinant IFN therapy is useful and alternative method in treatment of chronic hepatitis B. (Korean J Gastroenterol 1995;27:55-63)
B형 간염바이러스 표면항원과 항체가 동시에 발현된 만성 간염 환자에서 표면항원 `a` 결정기 유전자의 변이
박중원(Joong won Park),윤정환(Jung Hwan Yoon),황유진(You Jin Hwang),이효석(Hyo Suk Lee),김정룡(Chung Yong Kim) 대한소화기학회 1997 대한소화기학회지 Vol.29 No.2
N/A Background/Aims: A humoral escape mutant of hepatitis B virus(HBV) having mutations at HBsAg a' determinant has been found in patients with concurrent HBsAg and anti-HBs in sera. This study was undertaken to investigate whether such a variant was involved in Korean patients with chronic hepatitis B, Methods: We conducted an analysis of sequences of DNA encoding the HBsAg a' determinant in six chronic hepatitis B patients with concurrent HBsAg an6 anti-HBs positivity, and in three HBsAg-positive controls without anti-HBs in sera. One of the six cases 4ad received long-term hepatitis B immunoglobulin treatment after liver transplantation and five were chronic hepatitis B patients with naturally occurring concurrent HBsAg and anti-HBs. HBV DNA extracted from sera of nine patients was amplified and sequenced within the S gene encoding the a' determinant. Results: HBVs from three controls had no rnutations in the a determinant. Six patients with concurrent HBsAg and anti-HBs had point mutations in the S gene encoding the a' determinant. A liver-transplanted patient had substitutions at nucleotide 587(arginine for glycine at aa 143) and nucleotide 561(tyrosine for serine at aa 136) of the S gene. All of the five patients with naturally occurring concurrent HBsAg and anti-HBs had a substitution at nucleotide 531(serine for isoleucine at aa 126) and four of five had substitutions at nucleoti<le 546 and 552(asparagine for threonine at aa 131 and threonine for methionine at aa 133). One case had three consecutive substitutions at nucleotide 554, 555, 556(arginine for phenylalanine at aa 134). Conclusions: These results demonstrated the presence of mutations at HBsAg a detenninant in Korean chronic hepatitis B patients with concurrent HBsAg and anti-HBs. (Korean J (astroente- rol 1997;29:182 - 191)
SV 40 Large T 유전자를 이용해 불멸화시킨 사람 태아 간세포주의 확립
박중원(Joong Won Park),이주영(Joo Young Lee),이효석(Hyo Suk Lee),박주배(Joo Bae Park),김정룡(Chung Yong Kim) 대한내과학회 1994 대한내과학회지 Vol.46 No.4
Background: Hepatocyte culture represents a cell model for analyzing the mechanism involved in car- cinogenesis of carcinogens, a tool for measuring hepatotoxicity of drugs and a simple model for studying hepatitis virus life cycle. However, problems raised by both the short-term survival and the poor functional stability of hepatocytes in culture hindered scientist in using of this in vitro system. Thus we planed to obtain the immortalized and differentiated human hepatocyte cell line by modifying the genome by transfecting the cells with viral specific DNA, always available in studying the liver disease. Method: After primary culture of hepatocytes obtained by therapeutic abortion at 18 weeks of gestation, SV40 large T gene was transfected into the cells by using Polybren-DMSO method, And then transfected hepatocytes were selected in G418 containing medium. Selected, transformed hepatocytes were subcultured in 10% fetal bovine serum containg F-12 medium. Morphological characteristics of subcultured cells was followed by phase-contrast microscope and electoron microscope. The immunocytochemisty using anti-human albumin and anti-human alpha fetoprotein and the immunofluorescence using snti-SV40 T antigen were performed for proving the differentiation of sub-cultured hepatocytes. Results: Electron microscope revealed subcultured cell to be epithelial cell. After more than 20 passages over a period of 7 months, the cells retained an epitheloid morphology. All the SV40 transformed hepatocyte cell lines were 100% positive for T antigen. Significant anti-alpha fetoprotein staining and week anti-albumin staining were observed in cytoplasm around nucleus and so we confirmed the synthesis of liver specific protein of transformed hepatocytes, Conclusion: Human fetal immortalized hepatocytes cell line secreting the liver specific proteins was established.
간세포암종 환자의 5년 생존율 : 단일기관의 904명 코호트 연구
박경우 ( Kyung Woo Park ),박중원 ( Joong Won Park ),김태현 ( Tae Hyun Kim ),최준일 ( Jun Il Choi ),김성훈 ( Seong Hoon Kim ),박홍석 ( Hong Suk Park ),박상재 ( Sang Jae Park ),이우진 ( Woo Jin Lee ),신해림 ( Hae Lim Shin ),김창민 ( 대한간학회 2007 Clinical and Molecular Hepatology(대한간학회지) Vol.13 No.4
김보현,박중원,Bo Hyun Kim,Joong-Won Park 대한소화기암연구학회 2016 Journal of digestive cancer reports Vol.4 No.1
Hepatocellular carcinoma (HCC) is rather unique. Most of HCC patients have underlying chronic liver diseases with or without cirrhosis and the prognosis of HCC depends on the liver function, as well as the tumor extent. Non-invasive diagnosis of HCC can be made with certain risk factors and specific imaging findings (e.g. hypervascularity). Patients with HCC can receive surgical resection, radiotherapy, and systemic chemotherapy as other solid malignancies. HCC has more treatment options such as liver transplantation, transarterial chemoembolization (TACE) and radiofrequency ablation (RFA). A variety of practice guidelines for HCC has been published by many academic societies. Different healthcare systems and availability of resources also affect the practice guidelines; therefore, practice guidelines have similarities and dissimilarities. Herein, we review the current status of practice guidelines for HCC and future perspectives for the improvement of guidelines are also discussed.